T1	Participants 56 128	metastatic and/or unresectable malignant gastrointestinal stromal tumors
T2	Participants 351 454	patients with CD117(+) unresectable and/or metastatic malignant gastrointestinal stromal tumors (GISTs)
T3	Participants 852 917	(n = 946) and the other by the Southwest Oncology Group (n = 746)
